APA (7th ed.) Citation

X, R., P, V., L, B., AE, B., M, B., AS, P., . . . S, P. (2022). Subcutaneous injection of infliximab CT-P13 results in stable drug levels within 14-day treatment cycle in Crohn's disease. Alimentary pharmacology & therapeutics, 56(1), 77. https://doi.org/10.1111/apt.16852

Chicago Style (17th ed.) Citation

X, Roblin, et al. "Subcutaneous Injection of Infliximab CT-P13 Results in Stable Drug Levels Within 14-day Treatment Cycle in Crohn's Disease." Alimentary Pharmacology & Therapeutics 56, no. 1 (2022): 77. https://doi.org/10.1111/apt.16852.

MLA (9th ed.) Citation

X, Roblin, et al. "Subcutaneous Injection of Infliximab CT-P13 Results in Stable Drug Levels Within 14-day Treatment Cycle in Crohn's Disease." Alimentary Pharmacology & Therapeutics, vol. 56, no. 1, 2022, p. 77, https://doi.org/10.1111/apt.16852.